SCHEMBL12754209

SCHEMBL12754209

CCn1cc(-c2ccc(C(=O)O)cc2)nc1/C=C/c1ccc(-c2ccc(OCCCC(=O)O)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RARB P10826 5/20 0.47
PPARA Q07869 2/20 0.45
TP53 P04637 1/20 0.42
TSHR P16473 1/20 0.42
ALB P02768 1/20 0.42
PLA2G4B P0C869 1/20 0.41
CYSLTR2 Q9NS75 3/20 0.41
CYSLTR1 Q9Y271 3/20 0.41
DHFR P00374 2/20 0.40
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
PTPN11 Q06124 1/20 0.39
FFAR1 O14842 1/20 0.39
PPARG P37231 1/20 0.39
PPARD Q03181 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1481717 0.92 PPARA (0.52) PPARAALBCYSLTR2CYSLTR1CASP3
SCHEMBL1481721 0.92 PPARA (0.52) PPARAALBCYSLTR2CYSLTR1CASP3
SCHEMBL1481600 0.91 CASP3 (0.50) PPARAALBCYSLTR2CYSLTR1CASP3
SCHEMBL1481604 0.91 CASP3 (0.50) PPARAALBCYSLTR2CYSLTR1CASP3
SCHEMBL1480964 0.91 PPARA (0.42) RARBPPARAALBCYSLTR2CYSLTR1
SCHEMBL1480967 0.91 PPARA (0.42) RARBPPARAALBCYSLTR2CYSLTR1
SCHEMBL1481819 0.91 AGER (0.49) PPARAALBCYSLTR2CYSLTR1CASP3
SCHEMBL1481817 0.91 AGER (0.49) PPARAALBCYSLTR2CYSLTR1CASP3
SCHEMBL1481325 0.90 MMP2 (0.50) PPARAALBCYSLTR2CYSLTR1CASP3
SCHEMBL1481323 0.90 MMP2 (0.50) PPARAALBCYSLTR2CYSLTR1CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ RARB 2702/4885PPARA 2236/4885TP53 1088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.